Folate receptor alpha Inhibitors
1 drugsAbout Folate receptor alpha
Folate receptor alpha (FOLR1) is a glycosylated protein that binds folic acid, highly expressed in various cancers but limited in normal tissues. This makes it an attractive target for selective drug delivery to cancerous cells while sparing healthy ones.
FOLR1's overexpression in cancer makes it a compelling therapeutic target, despite the lack of direct genetic evidence linking it to disease. This selectivity is the basis for targeted therapies that aim to improve efficacy and reduce off-target effects.
ELAHERE is the only FDA-approved drug targeting FOLR1, representing an antibody-drug conjugate (ADC) for oncology. IMMUNOGEN INC is the sole company with an approved drug for this target.
Top Folate receptor alpha Drugs
IMMUNOGEN INC is the only company with an approved drug targeting FOLR1.
The single-player market indicates high barriers to entry or untapped potential for competitors.
Folate receptor alpha Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Folate receptor alpha, using adc modality.
The ADC-only landscape suggests a whitespace opportunity for alternative modalities like small molecules or bispecifics.
Folate receptor alpha Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Folate receptor alpha. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 4 | 1 | 1 | 80% |
| Phase 2 | 13 | 2 | 1 | 10 | 67% |
| Phase 3 | 5 | 3 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Folate receptor alpha Drug Approval Timeline (2022 - 2022)
The first and most recent drug approval for FOLR1 was ELAHERE in 2022.
Recent approval suggests growing interest, but the single data point indicates early stage of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 14 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Folate receptor alpha. A trial counts if an approved drug acting on Folate receptor alpha is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.